RxDoctor Payments Data

Jennifer Wurster, NP

Family · Tucson, AZNPI 1659740462

Payments from drug & device makers

$2,330in general payments, 2019–2025

Across 84 payments — averaging $27.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$428
  • Abbott$363
  • Amgen$325
  • Novo Nordisk$149
  • Neurocrine Biosciences, Inc.$128
  • Kestra Medical Technology Services, Inc.$121
  • plus $817 from 20 others

What the payments were for

  • Food & beverage$2,330100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,330 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$58,071
Medicare patients
220
Services billed
1,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide33$50,310
JardianceEmpagliflozin23$33,125
TrulicityDulaglutide16$18,771
RybelsusSemaglutide12$13,338
Gabapentin66$1,450
Levothyroxine Sodium119$1,393
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen37$1,282
Celecoxib12$1,212
Atorvastatin Calcium76$1,020
Albuterol Sulfate HfaAlbuterol Sulfate40$960
Lidocaine12$938
Estradiol (Once Weekly)Estradiol12$886
Oxycodone Hcl71$851
SynthroidLevothyroxine Sodium15$785
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen45$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$44$69,08149 claims
Boehringer IngelheimJardiance$40$33,12523 claims
Novo NordiskRybelsus$149$13,33812 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$32$1,393119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →